genaconazole

Genaconazole (SCH 39304) is a broad-spectrum triazole antifungal agent developed for oral and topical use. It demonstrated potent activity against a wide range of fungal pathogens, including *Trichophyton mentagrophytes* and *Candida albicans*, as well as *Aspergillus* species, *Cryptococcus neoformans*, *Blastomyces dermatitidis*, *Coccidioides immitis*, and *Histoplasma* species. Its mechanism of action is similar to other azole antifungals such as ketoconazole and fluconazole; it inhibits cell membrane ergosterol synthesis by blocking the demethylation of lanosterol. The clinical formulation was a racemic mixture containing two enantiomers—one active (SCH‑42427) and one inactive (SCH‑42426). Despite promising preclinical efficacy in animal models for superficial mycoses and systemic fungal infections—including vaginal candidiasis—development was discontinued due to hepatocarcinomas observed in animal studies[1][2][5][6].

Other names

genaconazoleSch 42426Sch42426Sch-42426Sch 42427Sch42427Sch-42427threo-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1h–1,2,4-triazol–1–yl)butan–2–ol